RxDoctor Payments DataLook up a doctor →

Marina Raikhel, MD

Family Medicine · Lomita, CANPI 1073792446

Payments from drug & device makers

$5,675,647in general payments, 2019–2025

Across 1,997 payments — averaging $2842.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$765K
  • Novo Nordisk AS$737K
  • Ironwood Pharmaceuticals, Inc$700K
  • AbbVie$522K
  • GSK$494K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$449K
  • plus $2M from 51 others
$13,770in research payments, 2019–2025

Across 88 payments — averaging $156.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$4K
  • Novo Nordisk$2K
  • Sanofi US Services Inc.$2K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • Gilead$1K
  • Novo Nordisk AS$1K
  • plus $936 from 1 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi US Services Inc.78$764,607
Novo Nordisk AS861$737,332
Ironwood Pharmaceuticals, Inc40$699,508
AbbVie(2 entities)209$522,323
GSK146$493,635
Otsuka Pharmaceutical Development & Commercialization, Inc.13$449,424
Novartis11$437,259
Avanir Pharmaceuticals, Inc.80$269,477
AstraZeneca40$205,402
Vanda Pharmaceuticals Inc.64$178,532
Lexicon Pharmaceuticals, Inc.57$171,459
Takeda Pharmaceuticals U.S.A., Inc.39$163,861
Pfizer(2 entities)53$129,347
CSL Behring43$120,463
Eisai Inc.21$71,590
Astellas Pharma Global Development31$63,881
Gilead9$28,331
Masimo Corporation29$27,192
Chiesi USA, Inc.11$24,448
Sumitomo Pharma America, Inc.5$21,035
Myovant Sciences Inc.1$18,693
Galderma Laboratories, L.p.7$14,381
GRT US Holding, Inc.1$12,540
Astellas Pharma US Inc13$9,416
Kowa Research Institute, Inc.3$9,255
Cipla USA Inc.11$8,369
Hikma Pharmaceuticals USA1$6,000
E.r. Squibb & Sons, L.L.C.3$4,139
Redhill Biopharma Inc.4$3,004
Shionogi Inc4$1,718
Biohaven Pharmaceuticals, Inc.5$1,514
Amgen(2 entities)16$1,460
Novo Nordisk25$946
Regeneron1$900
Bayer19$802
Esperion Therapeutics, Inc.3$348
Sanofi-aventis U.S. LLC4$326
Johnson & Johnson5$298
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$247
Regeneron Healthcare Solutions, Inc.2$241
BD2$240
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$239
Lilly USA, LLC5$193
Boehringer Ingelheim3$157
Madrigal Pharmaceuticals1$134
Halozyme Inc1$127
Sanofi1$126
Biohaven Pharmaceutical Holding Company Ltd.2$126
Lundbeck LLC2$125
Medtronic1$108
Exeltis, USA Inc.1$108
Merck1$99
Idorsia Pharmaceuticals US Inc1$86
Radius Health, Inc.1$24
Bausch Health US, LLC1$23
Vertiflex, Inc.1$17
Amarin Pharma, Inc.1$13

How this compares

$5,675,647 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Medicare billing

Part B allowed, 2024
$75,735
Medicare patients
84
Services billed
1,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Lomita

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →